Please login to the form below
Valneva
This page shows the latest Valneva news and features for those working in and with pharma, biotech and healthcare.
Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
Valneva will fund 40% of the remaining shared development costs, compared to 30% in the initial agreement. ... Pfizer will pay Valneva tiered royalties of up to 22% which will be complemented by up to $100m in milestones payable to Valneva based on
Latest news
-
EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
The European Medicines Agency (EMA) has accepted Valneva’s marketing authorisation application (MAA) for its COVID-19 vaccine candidate, VLA2001. ... Valneva’s vaccine candidate is currently the only whole virus, inactivated, adjuvanted candidate for
-
Pfizer and Valneva announce positive phase 2 paediatric data for lyme disease vaccine
Pfizer and Valneva have announced positive phase 2 paediatric results for their Lyme disease vaccine candidate, VLA15. ... The positive paediatric data marks an important step forward in the ongoing development of VLA15, and we are excited to continue
-
Valneva strikes European COVID-19 vaccine deal
The European Union intends to purchase up to 60 million doses of Valneva’s its inactivated COVID-19 vaccine VLA2001 by the end of 2023. ... Valneva CEO, Thomas Lingelbach, said the company continued to receive messages from people across the world who
-
Valneva COVID-19 vaccine more effective than AZ
Valneva will seek regulatory approval in the UK and European Union after its COVID-19 vaccine candidate performed well in phase 3 trials. ... Valneva hit the headlines this summer when the UK government cancelled a 1.4bn vaccine contract citing
-
Positive data for Lyme disease booster vaccine
A booster shot of Valneva/Pfizer’s VLA15 vaccine candidate against tick-borne Lyme disease demonstrates a strong immune response. ... Under the agreement, Valneva will fund 30% of the development costs and, in return, Pfizer will pay tiered royalties
More from news
Approximately 15 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Pharma deals during December 2012
The Vivalis shareholders will own 55 per cent of the new company called Valneva based in Lyon and the Intercell shareholders will obtain a 32 per cent premium for their shares.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Valneva expands management board
Appoints David Lawrence and Wolfgang Bender. Commercial stage biotech Valneva has appointed David Lawrence and Wolfgang Bender, a move that will strengthen the senior management team for future growth.
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
